-
公开(公告)号：KR101834005B1
公开(公告)日：2018-03-05
申请号：KR1020160102224
申请日：2016-08-11
Applicant: 서울대학교산학협력단 , 가톨릭대학교 산학협력단
Abstract: 본발명은티오우레아유도체의신규한용도에관한것으로서, 보다구체적으로는티오우레아유도체를유효성분으로포함하는자가면역질환예방또는치료용약학적조성물에관한것이다. 본발명에따른티오우레아유도체는 TNF-α, IL-1β, NOS2, IL-6 등의염증유전자의전사를억제할뿐만아니라, Th17의활성또는생성을억제하고, 조절 T 세포(Regulatory T cell: Treg)의활성또는생성을증가시킬수 있기때문에, 류마티스관절염을비롯한다양한자가면역질환의예방, 개선또는치료를위한약학적조성물, 건강식품조성물등에유용하게사용할수 있을것으로기대된다.
Abstract translation: 本发明涉及硫脲衍生物的新用途，更具体地涉及用于预防或治疗包含硫脲衍生物作为活性成分的自身免疫性疾病的药物组合物。 硫基根据本发明的尿素衍生物是TNF-α，IL-1β，NOS2，IL-6等，以及抑制炎性基因的转录，抑制Th17细胞和调节性T细胞（调节性T细胞的活性或产生的： Treg），预计其可用于预防，改善或治疗包括类风湿性关节炎的各种自身免疫疾病的药物组合物和保健食品组合物。
-
公开(公告)号：KR1020170020262A
公开(公告)日：2017-02-22
申请号：KR1020160102224
申请日：2016-08-11
Applicant: 서울대학교산학협력단 , 가톨릭대학교 산학협력단
CPC classification number: A61K31/17 , A23L33/10 , A23V2200/30 , A23V2200/324
Abstract: 본발명은티오우레아유도체의신규한용도에관한것으로서, 보다구체적으로는티오우레아유도체를유효성분으로포함하는자가면역질환예방또는치료용약학적조성물에관한것이다. 본발명에따른티오우레아유도체는 TNF-α, IL-1β, NOS2, IL-6 등의염증유전자의전사를억제할뿐만아니라, Th17의활성또는생성을억제하고, 조절 T 세포(Regulatory T cell: Treg)의활성또는생성을증가시킬수 있기때문에, 류마티스관절염을비롯한다양한자가면역질환의예방, 개선또는치료를위한약학적조성물, 건강식품조성물등에유용하게사용할수 있을것으로기대된다.
-
公开(公告)号：KR101337767B1
公开(公告)日：2013-12-09
申请号：KR1020110074144
申请日：2011-07-26
Applicant: 서울대학교산학협력단
CPC classification number: C07K14/475 , A61K38/00
Abstract: 본 발명은 HIF-1α 유전자를 활성화시켜 상처치료에 중요한 혈관내피세포성장인자(VEGF)의 전사 활성을 증가시키는 신규한 펩타이드 및 이를 포함하는 약학적 조성물 등을 제공한다. 상기 본 발명의 약학적 조성물은 상처치료, 피부 조직 재생과 발모 촉진 등의 효과를 가진다.
-
Patent Agency Ranking
公开(公告)号：KR101450960B1
公开(公告)日：2014-10-22
申请号：KR1020120054540
申请日：2012-05-23
Applicant: 서울대학교산학협력단
IPC: C07C335/12 , A61K31/145 , A61P3/06 , A61P1/16
CPC classification number: C07C335/12
Abstract: 본 발명은 RORα 유전자를 활성화시키는 신규한 화합물 또는 그의 염에 관한 것이다. 구체적으로 본 발명은 thiazolidinedione의 하나인 CGP52608을 선도 물질로 하는 신규한 JC1 화합물 또는 이의 약제학적으로 허용가능한 염을 제공한다. 또한, 본 발명은 유효성분으로 상기 신규한 화합물을 포함하는 지질 축적 억제제를 제공한다. 본 발명은 대사성 질환 또는 염증성 질환 치료에 적용될 수 있을 것으로 기대된다.
-
公开(公告)号：KR1020120130733A
公开(公告)日：2012-12-03
申请号：KR1020120054540
申请日：2012-05-23
Applicant: 서울대학교산학협력단
IPC: C07C335/12 , A61K31/145 , A61P3/06 , A61P1/16
CPC classification number: C07C335/12
Abstract: PURPOSE: A compound is provided to treat and prevent metabolic diseases and inflammatory diseases through various biofunctions of RORα, being especially useful for preventing and treating liver aliments by controlling cholesterol homeostasis and suppression of lipids. CONSTITUTION: A compound is represented by chemical formula 1. In chemical formula 1, R is hydrogen or a C1-3 alkyl group, R2 is hydrogen, a halogen, a C1-3 alkyl, a C1-3 alkoxy, a nitro group, a hydroxyl group, or a phenoxy group, R3 is hydrogen, a halogen, a C1-3 alkyl group, a C1-3 alkoxy group, a nitro group, a hydroxy group, or a phenoxy group, R4 is hydrogen, a halogen, a C1-3 alkyl group, a C1-3 alkoxy group, a nitro group, a hydroxy group, a cyano group, a dimethylamino group, a methylsulfonylamide group, a trifluoromethyl group, a binylbenzene group, a phenoxy group, a benzoxy group, a aryl group, or a phenylamine group, R5 is hydrogen, a halogen, a C1-3 alkyl group, a C1-3 alkoxy group, a nitro group, a hydroxy group, or aphenoxy group.
Abstract translation: 目的：提供一种化合物，通过RORα的各种生物功能治疗和预防代谢疾病和炎症疾病，特别适用于通过控制胆固醇体内平衡和抑制脂质来预防和治疗肝脏营养。 化学式为化学式1中，R为氢或C 1-3烷基，R 2为氢，卤素，C 1-3烷基，C 1-3烷氧基，硝基， 羟基或苯氧基，R3是氢，卤素，C1-3烷基，C1-3烷氧基，硝基，羟基或苯氧基，R4是氢，卤素， C 1-3烷基，C 1-3烷氧基，硝基，羟基，氰基，二甲基氨基，甲基磺酰胺基，三氟甲基，乙烯基苯基，苯氧基，苯氧基， 芳基或苯胺基，R 5为氢，卤素，C 1-3烷基，C 1-3烷氧基，硝基，羟基或苯氧基。
-
公开(公告)号：KR102050949B1
公开(公告)日：2019-12-03
申请号：KR1020180018435
申请日：2018-02-14
Applicant: 서울대학교산학협력단
IPC: C12Q1/6886 , G01N33/574
-
公开(公告)号：KR1020130014700A
公开(公告)日：2013-02-08
申请号：KR1020110074144
申请日：2011-07-26
Applicant: 서울대학교산학협력단
CPC classification number: C07K14/475 , A61K38/00
Abstract: PURPOSE: A pharmaceutical composition containing a novel peptide which enhances transcription activity of VEGF(Vascular Endothelial Growth Factor) is provided to activate VEGF gene through HIF-1alpha activation and to promote wound healing, skin tissue regeneration, and hair growth. CONSTITUTION: A pharmaceutical composition for wound healing and skin tissue regeneration contains a peptide with a base sequence selected from sequence numbers 1-3. The peptide enhances the expression of HIF-1alpha, VEGF, fibronectin, or collagen. The peptide proliferates VEGF and enhances cell migration. A method for wound healing or skin tissue regeneration comprises a step of administering the pharmaceutical composition to an individual. [Reference numerals] (AA) Gauze; (BB) Existing salve; (CC) Base; (DD) **p
Abstract translation: 目的：提供一种含有增强VEGF转录活性的新肽（血管内皮生长因子）的药物组合物，通过HIF-1α活化激活VEGF基因，促进伤口愈合，皮肤组织再生和毛发生长。 构成：用于伤口愈合和皮肤组织再生的药物组合物含有具有选自序列号1-3的碱基序列的肽。 该肽增强了HIF-1α，VEGF，纤连蛋白或胶原蛋白的表达。 肽增殖VEGF并增强细胞迁移。 用于伤口愈合或皮肤组织再生的方法包括向个体施用药物组合物的步骤。 （标号）（AA）纱布; （BB）现有药物; （CC）基地; （DD）** p <0.01和*** p <0.001与基础对照（碱）相比，
-
公开(公告)号：KR1020120130678A
公开(公告)日：2012-12-03
申请号：KR1020110128903
申请日：2011-12-05
Applicant: 서울대학교산학협력단
IPC: C07C335/12 , A61K31/17 , A61P3/00 , A61P29/00
Abstract: PURPOSE: A compound is provided to prevent and treat inflammatory diseases and metabolic disease through various biofunctions, being especially useful for preventing and treating liver ailments by controlling cholesterol homeostasis and suppressing the synthesis of lipids. CONSTITUTION: A compound is indicated in chemical formula 1. In chemical formula 1, R1 is hydrogen or a C1-3 alkyl, each of R2 and R3 is hydrogen, or a C1-3 alkyl, alkoxy, hydroxy, nitro, hydroxy or phenoxy group. R4 is hydrogen, a halogen, or a C1-3 alkyl, alkoxy, nitro, hydroxy, cyano, dimethylamino, methylsulfonylamide, trifluoromethyl, vinyl benzene, phenoxy, benzoxy, aryl or phnylamine group, R5 is hydrogen, halogen, or a C1-3 alkyl, alkoxy, nitro, hydroxy or phenoxy group.
Abstract translation: 目的：提供一种化合物，通过各种生物功能预防和治疗炎症性疾病和代谢疾病，特别适用于通过控制胆固醇体内平衡和抑制脂质合成来预防和治疗肝脏疾病。 化学式为化学式1中，R1为氢或C1-3烷基，R2和R3分别为氢或C1-3烷基，烷氧基，羟基，硝基，羟基或苯氧基 组。 R4是氢，卤素或C1-3烷基，烷氧基，硝基，羟基，氰基，二甲基氨基，甲基磺酰胺，三氟甲基，乙烯基苯，苯氧基，苯氧基，芳基或芳基，R5是氢，卤素或C1- 3烷基，烷氧基，硝基，羟基或苯氧基。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.032 seconds)
